CN114727981B - 用于挽救视网膜和脉络膜结构和功能的组合物和方法 - Google Patents

用于挽救视网膜和脉络膜结构和功能的组合物和方法

Info

Publication number
CN114727981B
CN114727981B CN202080077308.XA CN202080077308A CN114727981B CN 114727981 B CN114727981 B CN 114727981B CN 202080077308 A CN202080077308 A CN 202080077308A CN 114727981 B CN114727981 B CN 114727981B
Authority
CN
China
Prior art keywords
retinal
hemichannel
choroidal
function
connexin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080077308.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114727981A (zh
Inventor
科林·理查德·格林
纳西尔·马特·诺尔
莫妮卡·利利亚娜·阿科斯塔·埃切巴內
布拉德福德·詹姆斯·杜夫特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onex Medical Co ltd
Auckland Uniservices Ltd
Original Assignee
Onex Medical Co ltd
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onex Medical Co ltd, Auckland Uniservices Ltd filed Critical Onex Medical Co ltd
Priority to CN202511903254.9A priority Critical patent/CN121846082A/zh
Publication of CN114727981A publication Critical patent/CN114727981A/zh
Application granted granted Critical
Publication of CN114727981B publication Critical patent/CN114727981B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080077308.XA 2019-09-13 2020-09-11 用于挽救视网膜和脉络膜结构和功能的组合物和方法 Active CN114727981B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511903254.9A CN121846082A (zh) 2019-09-13 2020-09-11 用于挽救视网膜和脉络膜结构和功能的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900379P 2019-09-13 2019-09-13
US62/900,379 2019-09-13
US201962903504P 2019-09-20 2019-09-20
US62/903,504 2019-09-20
PCT/US2020/050579 WO2021051015A1 (en) 2019-09-13 2020-09-11 Compositions and methods for rescuing retinal and choroidal structure and function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511903254.9A Division CN121846082A (zh) 2019-09-13 2020-09-11 用于挽救视网膜和脉络膜结构和功能的组合物和方法

Publications (2)

Publication Number Publication Date
CN114727981A CN114727981A (zh) 2022-07-08
CN114727981B true CN114727981B (zh) 2026-03-31

Family

ID=74866757

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080077308.XA Active CN114727981B (zh) 2019-09-13 2020-09-11 用于挽救视网膜和脉络膜结构和功能的组合物和方法
CN202511903254.9A Pending CN121846082A (zh) 2019-09-13 2020-09-11 用于挽救视网膜和脉络膜结构和功能的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511903254.9A Pending CN121846082A (zh) 2019-09-13 2020-09-11 用于挽救视网膜和脉络膜结构和功能的组合物和方法

Country Status (6)

Country Link
US (1) US20220401408A1 (https=)
EP (1) EP4027992A4 (https=)
JP (2) JP2022547324A (https=)
CN (2) CN114727981B (https=)
CA (1) CA3154499A1 (https=)
WO (1) WO2021051015A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025219925A1 (en) * 2024-04-19 2025-10-23 Auckland Uniservices Limited Compounds for treatment and prevention of diseases, disorders and conditions
WO2025219923A1 (en) * 2024-04-19 2025-10-23 Auckland Uniservices Limited Modulators for treatment and prevention of diseases, disorders and conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281524A1 (en) * 2008-06-05 2013-10-24 Peter Blower Novel treatments
EP2506847A1 (en) * 2009-12-03 2012-10-10 Proximagen Limited Treatment of infectious diseases
US10465188B2 (en) * 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
JP6898848B2 (ja) * 2014-09-19 2021-07-07 メモリアル スローン ケタリング キャンサー センター 脳転移を治療するための方法

Also Published As

Publication number Publication date
JP2025181930A (ja) 2025-12-11
CA3154499A1 (en) 2021-03-18
EP4027992A1 (en) 2022-07-20
US20220401408A1 (en) 2022-12-22
JP2022547324A (ja) 2022-11-11
CN114727981A (zh) 2022-07-08
WO2021051015A1 (en) 2021-03-18
EP4027992A4 (en) 2023-11-29
CN121846082A (zh) 2026-04-14

Similar Documents

Publication Publication Date Title
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
HRP20040406A2 (en) Methods for treating ocular neovascular diseases
CN114845718B (zh) 用于治疗与过度血管形成相关的眼部疾病的化合物
JP2025181930A (ja) 網膜および脈絡膜の構造ならびに機能を回復させるための組成物および方法
US20060293270A1 (en) Methods and compositions for treating ocular disorders
JP2020500938A (ja) 黄斑変性症の新しい治療法
Lambert et al. Nanosponge-mediated drug delivery lowers intraocular pressure
RU2744878C2 (ru) Ингибиторы дипептидилпептидазы-4 для местного офтальмологического лечения нейродегенеративных заболеваний сетчатки
WO2016156639A1 (es) Formulación tópica oftálmica de antagonistas del receptor de la endotelina
JP7436067B2 (ja) ナノ低分子ペプチドｆｇ及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用
JP7461667B2 (ja) ナノ低分子ペプチドｆｈ及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用
HK40080560A (en) Compositions and methods for rescuing retinal and choroidal structure and function
TWI848332B (zh) 抗血管生成之自組裝奈米粒子及其用途
AU2022206798B2 (en) Self-assembled nanoparticle and use thereof for anti- angiogenesis
Le The Neuroprotective Effects of SA-10 PLGA Nanoparticles in a Mouse Model of Retinal Ischemia/Reperfusion Injury
HK1173084A (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080560

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant